Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes
Launched by CHUNGBUK NATIONAL UNIVERSITY HOSPITAL · Mar 15, 2018
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Are inadequately controlled with triple OADs (metformin, sulfonylurea, dipeptidyl peptidase inhibitor) as evidenced by HbA1c \>7.5% and \<12.0%
- Exclusion Criteria:
- • Type 1 diabetes
- • Gestional diabetes
- • Diabetes due to secondary causes
- • Receiving anticancer treatment
- • Receiving glucocorticoids or immune-suppressants
- • Have been treated with sodium glucose co-transporter 2 inhibitors for more than 7 consecutive days within 3 months before entering the study
- • Have been treated with any type of insulin for more than 7 consecutive days within 3 months before entering the study
About Chungbuk National University Hospital
Chungbuk National University Hospital is a leading medical institution located in South Korea, dedicated to advancing healthcare through comprehensive clinical research and innovative patient care. As a prominent academic hospital affiliated with Chungbuk National University, it integrates cutting-edge medical practices with rigorous scientific inquiry. The hospital is committed to facilitating high-quality clinical trials across various specialties, fostering collaboration among researchers, healthcare professionals, and regulatory bodies to enhance patient outcomes and contribute to the global medical community. With a strong emphasis on ethics and patient safety, Chungbuk National University Hospital plays a pivotal role in translating research findings into effective clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials